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Abstract 
A toxicovenomic analysis of the venom of the forest cobra, N. melanoleuca, 
was performed, revealing the presence of a total of 52 proteins by proteomics 
analysis. The most abundant proteins belong to the three-finger toxins (3FTx) (57.1 
w%), which includes post-synaptically acting D-neurotoxins. Phospholipases A2 
(PLA2) were the second most abundant group of proteins (12.9 w%), followed by 
metalloproteinases (SVMPs) (9.7 w%), cysteine-rich secretory proteins (CRISPs) (7.6 
w%), and Kunitz-type serine proteinase inhibitors (3.8 w%). A number of additional 
protein families comprised each less than 3 w% of venom proteins. A toxicity 
screening of the fractions, using the mouse lethality test, identified toxicity in RP-
HPLC peaks 3, 4, 5 and 8, all of them containing D-neurotoxins of the 3FTx family, 
whereas the rest of the fractions did not show toxicity at a dose of 0.53 mg/kg. Three 
polyspecific antivenoms manufactured in South Africa and India were tested for their 
immunoreactivity against crude venom and fractions of N. melanoleuca. Overall, 
antivenoms immunorecognized all fractions in the venom, the South African 
antivenom showing a higher titer against the neurotoxin-containing fractions. This 
toxicovenomic study identified the 3FTx group of D-neurotoxins in the venom of N. 
melanoleuca as the relevant targets to be neutralized. 
 
(200 words) 
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Biological significance 
A toxicovenomic analysis of the venom of the forest cobra, also known as black 
cobra, Naja melanoleuca, was performed. Envenomings by this elapid species are 
characterized by a progressive descending paralysis which starts with palpebral ptosis 
and, in severe cases, ends up with respiratory arrest and death. A total of 52 different 
proteins were identified in this venom. The most abundant protein family was the 
three-finger toxin (3FTx) family, which comprises almost 57.1 w% of the venom, 
followed by phospholipases A2 (PLA2) (12.9 w%). In addition, several other protein 
families were identified in a much lower percentage in the venom. A toxicity 
screening of the fractions, using the mouse lethality assay, identified four peaks as 
those having toxicity higher than that of the crude venom. These fractions 
predominantly contain D-neurotoxins of the 3FTx family. This toxicovenomic 
characterization agrees with the clinical and experimental manifestations of 
envenomings by this species, in which a strong neurotoxic effect predominates. 
Therefore, our findings suggest that immunotherapy against envenomings by N. 
melanoleuca should be directed towards the neutralization of 3FTxs; this has 
implications for the improvement of current antivenoms and for the development of 
novel antivenoms based on biotechnological approaches.  A screening of the 
immunoreactivity of three antivenoms being distributed in sub-Saharan Africa 
revealed that they immunoreact with the fractions containing D-neurotoxins, although 
with different antibody titers. 
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1. Introduction 
The forest cobra, also known as the black cobra (Naja melanoleuca), is a 
highly venomous member of the elapid snake family, reaching up to 3.1 meters in 
length, and being able to deliver venom yields above 1 gram per milking [1]. N. 
melanoleuca is the largest of the African cobra species and it is known to inhabit 
moist river areas, primary and secondary forests, and suburban habitats in Western, 
Central, and Southern Africa [2–4]. Its coloration may vary between three different 
color morphs, and it is active during the day, where it feeds on mammals, frogs, and 
fish [2,3]. From the clinical standpoint, envenomings by N. melanoleuca have been 
classified within the syndromic category 3, characterized by progressive paralysis 
(neurotoxicity) [5]. Patients develop a descending progressive paralysis which starts 
with ptosis, external ophtalmoplegia and weakness of muscles innervated by the 
cranial nerves, with patients having difficulties in swallowing and speaking. 
Eventually the respiratory muscles become paralyzed, and death ensues unless 
mechanical ventilation is provided [5].  
Currently, six antivenoms are claimed to be effective against envenomings 
from N. melanoleuca [6]. Due to the severity of envenomings, N. melanoleuca is 
classified by the WHO as a category 1 snake of highest medical importance 
(http://apps.who.int/bloodproducts/snakeantivenoms/database/). Therefore, it is of 
high relevance to obtain a deep understanding of the composition of N. melanoleuca 
venom. To this date, no quantitative venom proteome has been reported for N. 
melanoleuca, however, several biochemical studies have reported that the venom 
contains long and short neurotoxins [7,8], cytotoxins [9–11], phospholipases A2 
[12,13], and 'weak' toxins [9,14].  
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In order to develop safe and effective antivenoms that can protect against 
envenoming from N. melanoleuca, it is not only important to know the venom 
composition. It is also essential to understand which toxins are the medically most 
relevant to target. For this purpose, the combination of venomics and the Toxicity 
Score [15] may be employed to unveil which toxins are the main culprits responsible 
for the clinical manifestations of N. melanoleuca envenomings. Being able to identify 
these key toxins may not only help guide traditional antivenom development, but may 
also aid rational antitoxin discovery approaches based on biotechnology [16]. 
 Here, we report the first toxicovenomics study of the venom of N. 
melanoleuca, providing a quantitative estimation of its proteome alongside an 
assessment of the medical importance of the individual venom fractions and an 
evaluation of the immunorecognition pattern of three antivenoms in use in sub-
Saharan Africa. 
 
2. Materials and Methods 
2.1 Snake venom 
 Venom of N. melanoleuca was obtained from Latoxan SAS, Valence, France, 
from a pool of 7 specimens collected in Uganda. Venoms from N. nigricollis and N. 
mossambica used for comparison in in vitro enzymatic assays were also obtained 
from Latoxan from pools of several specimens collected in Tanzania. Venom from 
Bothrops asper was obtained as a pool from several specimens from Costa Rica kept 
at Instituto Clodomiro Picado, Universidad de Costa Rica, Costa Rica. 
 
2.2 Venom separation by reverse-phase HPLC and SDS-PAGE  
Following the ‘snake venomics’ analytical strategy, crude venom was 
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fractionated involving a combination of RP-HPLC and SDS-PAGE separation [17]. 
Two mg of venom was dissolved in 200 μL of water containing 0.1% trifluoroacetic 
acid (TFA; solution A) and separated by RP-HPLC (Agilent 1200) on a C18 column 
(250 x 4.6 mm, 5 μm particle; Supelco). Elution was carried out at 1 mL/min by 
applying a gradient towards solution B (acetonitrile, containing 0.1% TFA): 0% B for 
5 min, 0–15% B over 10 min, 15–45% B over 60 min, 45–70% B over 10 min, and 
70% B over 9 min, as previously described [18]. Fractions were collected manually, 
dried in a vacuum centrifuge, redissolved in water, reduced with 5% E-
mercaptoethanol at 100°C for 5 min, and further separated by SDS-PAGE in 15% 
gels. Colloidal Coomassie blue G-250 was used for proteins staining, and a 
ChemiDoc® recorder and ImageLab® software (Bio-Rad) were used to acquire gel 
images. 
 
2.3 Protein identification by tandem mass spectrometry of tryptic peptides 
From the polyacrylamide gels protein bands were excised and subjected to 
reduction (10 mM dithiothreitol), alkylation (50 mM iodoacetamide), and overnight 
in-gel digestion with sequencing grade trypsin (Sigma), in 50 mM ammonium 
bicarbonate at 37 °C. Tryptic peptides were extracted with 50% acetonitrile 
containing 1% TFA, and analyzed by MALDI-TOF-TOF on an AB4800-Plus 
Proteomics Analyzer (Applied Biosystems). Digested and extracted peptides were 
mixed with an equal volume of saturated α-cyano-hydroxycinnamic acid (in 50% 
acetonitrile, 0.1% TFA), and spotted (1 μL) onto an Opti-TOF 384-well plate, dried, 
and analyzed in positive reflector mode. TOF spectra were acquired using 500 shots 
at a laser intensity of 3000. TOF/TOF fragmentation spectra were acquired using 500 
shots at a laser intensity of 3900 for the automatically selected ten most intense 
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precursor ions. CalMix® standards (ABSciex) spotted onto the same plate were used 
for external calibration in each run. Resulting spectra were searched against the 
UniProt/SwissProt database for Serpentes (20150217) using ProteinPilot® v.4 and the 
Paragon® algorithm (ABSciex) at ≥ 95% confidence, or, in few cases, manually 
interpreted, and the deduced sequences searched using BLAST 
(http://blast.ncbi.nlm.nih.gov) for assignment of protein family by similarity. 
 
2.4 Relative protein abundance estimations 
 The relative abundance of the venom proteins was estimated using the 
ChemStation® software (Agilent) to integrate the areas of their chromatographic 
peaks at a wavelength of 215 nm, roughly corresponding to peptide bond abundance 
[17]. When HPLC peaks contained several electrophoretic bands, ImageLab® (Bio-
Rad) was used to assign their percentage distributions by densitometry. Finally, for 
electrophoretic bands containing more than one protein according to MALDI-TOF-
TOF analysis, their percentage distributions were estimated based on the 
corresponding intensities of the intact protein ions, as observed in the nESI-MS 
analysis. For this, a 10 PL sample of the HPLC fraction was loaded into a metal-
coated capillary (Proxeon) and directly infused into a nano-spray source of a QTrap 
3200 mass spectrometer (Applied Biosystems) operated at 1300 V in enhanced multi-
charge mode. Deconvolution of spectra was performed with the aid of the Bayesian 
protein reconstruction tool of Analyst v.1.5. Intensities lower than 5% (relative to the 
major protein ions in these mixtures) were considered as traces. Protein abundances 
were calculated on the basis of protein content percentage (w%).  
 
2.5 In vitro enzymatic activities 
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2.5.1. Phospholipase A2 activity 
PLA2 activity was assayed using the monodisperse synthetic chromogenic 
substrate 4-nitro-3-octanoyloxybenzoic acid (NOBA) [19]. 25 μL of solution, 
containing various amounts of venom, were mixed with 200 μL of 10 mM Tris, 10 
mM CaCl2, 0.1 M NaCl, pH 8.0, and 25 μL of NOBA to achieve a substrate 
concentration of 0.32 mM. Plates were incubated at 37 °C for 60 min, and 
absorbances were recorded at 405 nm (Multiskan FC, Thermo Scientific). For 
comparative purposes, the activities of the venoms of N. mossambica, N. nigricollis, 
and the viperid snake Bothrops asper were also assessed. 
 
2.5.2 Proteinase activity 
 Proteinase activity was assayed by adding 20 µg of venom to 100 μL of 
azocasein (10 mg/mL in 50 mM Tris–HCl, 0.15 M NaCl, 5 mM CaCl2 buffer, pH 
8.0), and the mixture was incubated for 90 min at 37 °C. The reaction was terminated 
by addition of 200 μL of 5% trichloroacetic acid. After centrifugation (5 min, 6,000 × 
g), 150 μL of supernatants were mixed with 100 μL of 0.5 M NaOH, and absorbances 
were recorded at 450 nm (Multiskan FC, Thermo Scientific). The absorbance of 
azocasein incubated with distilled water alone was used as a blank, being subtracted 
from all readings [20]. For comparative purposes, the activities of the venoms of N. 
mossambica, N. nigricollis, and Bothrops asper were also assessed. 
 
2.6 Toxicological profiling 
2.6.1 Animals  
 In vivo assays were performed in CD-1 mice of both sexes, provided by 
Instituto Clodomiro Picado, following protocols approved by the Institutional 
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Committee for the Use and Care of Animals (CICUA), University of Costa Rica. 
Mice were provided food and water ad libitum. 
 
2.6.2 Toxicity of crude venom and isolated venom fractions 
 The acute toxicity of venom fractions was initially screened by intravenous 
(i.v.) injection of 10 μg of toxin per mouse (0.53 mg/kg) for all fractions devoid of 
snake venom metalloproteinases (SVMPs) in groups of three mice (18–20 g body 
weight). Fractions that were not lethal at this level were not further investigated, 
whereas precise LD50s were determined in groups of four mice for fractions which did 
kill mice at this dose, and for the whole venom. Toxicity Scores were calculated 
according to Laustsen et al. [15], on the basis of the abundance (w%) of each fraction. 
Additionally, a Molecular Toxicity Score was introduced, which was calculated using 
the molecular abundance (mol%) of each fraction based on the molecular mass of 
identified toxins. Various amounts of venom or venom fractions were dissolved in 
phosphate-buffered saline (PBS; 0.12 M NaCl, 0.04 M sodium phosphate buffer, pH 
7.2) and injected in the caudal vein, in a volume of 100 µL. Deaths occurring within 
24 h were recorded, and LD50s were calculated by probits [21], using the BioStat® 
software (AnalySoft). 
 
2.7 Antivenoms 
 Polyspecific antivenoms from the following manufacturers were employed: (a) 
SAIMR (South African Institute for Medical Research) Polyvalent Snake Antivenom 
from South African Vaccine Producers (Pty) Ltd (batch number BC02645, expiry 
date 07/2016); (b) Snake Venom Antivenom (Central Africa) from VINS Bioproducts 
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Ltd (batch 12AS13002, expiry date 04/2017); (c) Snake Venom Antivenom (African) 
from VINS Bioproducts Ltd (batch 13022, expiry date 01/2018). 
 
2.8 Immunoreactivity of antivenoms against crude venom and venom fractions by 
ELISA 
 Wells in MaxiSorp™ plates (NUNC, Roskilde, Denmark) were coated with 1 
μg of each HPLC venom fraction, or crude venom, dissolved in 100 μL PBS 
overnight. Next day, the wells were washed three times with PBS and blocked by 
adding 100 μL PBS containing 2% (w:v) bovine serum albumin (BSA, Sigma), and 
incubated at room temperature for 1 h. Then, plates were washed five times with PBS. 
A dilution of each antivenom in PBS + 2% BSA was prepared, and 100 μL of these 
solutions were added to each well in triplicates and incubated for 2 h. Plates were then 
washed five times with PBS. Subsequently, 100 µL of a 1:2000 dilution of conjugated 
antibody (Sigma A6063, rabbit anti-horse IgG (whole molecule)-alkaline phosphatase 
in PBS + 1% BSA) was then added to each well. Following 2 h of incubation, the 
wells were washed five times with FALC buffer (0.05 M Tris, 0.15 M NaCl, 20 PM 
ZnCl2, 1 mM MgCl2, pH 7.4). Color development was achieved by addition of 100 
µL p-nitrophenyl phosphate (1 mg/mL in 9.7% v/v diethanolamine buffer, pH 9.8) 
and absorbances at 405 nm were recorded (Multiskan FC, Thermo Scientific). 
 
3.0 Results and Discussion 
3.1 Venomics 
A bottom-up venomic characterization of N. melanoleuca venom was performed. 
Using RP-HPLC, the venom was resolved into 33 fractions, where the first, second 
and sixth fractions eluting from the column did not contain proteins as found in SDS-
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PAGE. Further resolving by SDS-PAGE of the 30 remaining fractions yielded 63 
bands (Figure 2), of which the protein identities for 62 bands were positively 
identified upon in-gel digestion and MALDI-TOF-TOF analysis. Within these bands a 
total of 52 different proteins were identified. As described previously [22,23], some 
fractions contained toxins in both monomer and dimer form, as exemplified by 
fraction number 10 (see Figure 2). To uncover the overall protein composition of N. 
melanoleuca venom, the identified proteins were assigned to families and expressed 
as percentages of total protein content (see Figure 3 and Table 1). The most abundant 
proteins were found to belong to the three-finger toxin (3FTx) family (57.1 w%), 
followed by proteins from the phospholipase A2 (PLA2) family (12.9 w%) (Figure 3). 
3FTxs in elapid venoms share a common structural scaffold consisting of 60-80 
amino acids, with three E-stranded loops extending from a small, globular, 
hydrophobic core [24–26]. Despite this highly conserved structure, 3FTxs display a 
wide range of activities [27], although the main 3FTxs identified in the venom of N. 
melanoleuca are type I and II D-neurotoxins and cytotoxins (see Table 1). Both type I 
and II D-neurotoxins target the nicotinic acetylcholine receptor at the end-plate of 
muscle fibers, causing flaccid paralysis in victims and prey, potentially culminating in 
respiratory failure and death [28–30]. The cytotoxins identified in this study derive 
from the type IA cytotoxin sub-subfamily. Cobra cytotoxins are amphiphilic toxins 
known for inducing cellular damage through disruption of the cell membrane, which 
may lead to tissue necrosis [31,32]. However, experimental and clinical envenomings 
by N. melanoleuca are not characterized by tissue necrosis possibly due to the 
relatively low content of cytotoxins as compared to the predominant D-neurotoxins.  
The second-most abundant toxin family found in the venom of N. melanoleuca 
is the phospholipase A2 (PLA2) family (12.9 w%), which is generally found in 
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abundance in both viperids and elapids and, in the case of elapids, has evolved from 
pancreatic PLA2 digestive enzymes [33]. The catalytic function of PLA2s is to cleave 
phospholipids at the sn-2 position in the glycerol backbone. In snake venoms, 
however, PLA2s not only play a role in the digestion of prey, but also exhibit a variety 
of toxicological effects [34]. As in other elapid venoms, the PLA2s found in N. 
melanoleuca belong to the Group I, catalytically-active D49 enzymes [33]. In 
agreement, N. melanoleuca venom showed PLA2 activity, similar to the venom of N. 
nigricollis but lower than that of venoms of N. mossambica and Bothrops asper 
(Figure 4A). Despite the presence of 9.7% SVMPs in the venom proteome, very low 
proteinase activity was observed on azocasein (Figure 4B). It is likely that the SVMPs 
of N. melanoleuca have restricted substrate specificity as observed in other elapid 
species [22,23] 
Other protein families found in lower proportions in the venom of N. 
melanoleuca include cysteine-rich secretory proteins (CRISP; 7.6 w%), Kunitz-type 
serine proteinase inhibitors (BPTI/Kunitz; 3.8 w%), flavin monoamine oxidases 
(FMO; 2.5 w%), and traces of nerve growth factors (NGF < 0.4 w%), ohanin/vespryn 
family (OHA; < 0.5 w%), DNA/RNA endonucleases (DRE < 0.3 w%), 
endonuclease/phosphodiesterase (PDE; 1.1 w%), glutathione peroxidase family (GPF; 
0.9 w%), type-B carboxylesterase/lipase family (CELF; 1.1 w%), and selectins 
(SUSHI; < 0.3 w%). 
 
3.2. Toxicity of venom fractions 
Toxicity testing was carried out for all venom fractions devoid of SVMPs, since the 
solvents used for RP-HPLC denature these proteinases (Table 2). First, the LD50 of 
crude venom was determined to be 0.66 mg/kg (95% confidence interval 0.49-0.92 
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mg/kg). This value was higher than previously determined LD50s (i.v. 0.289 mg/kg), 
reported on http://snakedatabase.org/pages/LD50.php. It is likely that this can be 
explained by geographical variation in venom toxicity which is known to occur in 
species having a wide distribution [35]. A cut-off value of 10 µg per mouse (0.53 
mg/kg) was chosen for toxicity screening of the venom fractions. From Table 2 it was 
evident that the majority of fractions inducing lethality within 24 h were those 
containing type I and II α-neurotoxins. LD50s were determined for fractions that 
showed lethality at 0.53 mg/kg, more specifically fractions 3, 4, 5, and 8, as depicted 
in Table 2. These LD50s were lower than the overall LD50 of the crude venom 
suggesting that the toxins present in these fractions are of high medical relevance. 
According to their Toxicity Scores, the most potent fraction was fraction 8 (TS = 88, 
Molecular TS = 115.5), containing a homolog of Long neurotoxin OH-55 
Ophiophagus hannah (Q53B58), Long neurotoxin 2 Naja melanoleuca (P01338), and 
Weak toxin S4C11 Naja melanoleuca (P01400). Previous studies have found Weak 
toxin S4C11 Naja melanoleuca (P01400) to have an LD50 of 20 mg/kg [9], strongly 
suggesting that the long neurotoxins are the cause of the high toxicity of this fraction. 
From the MALDI-TOF-TOF analysis fractions 3, 4, and 5 were found to contain 
similar D-neurotoxins, with all three fractions having LD50s in the same range. Due to 
differences in abundances, Toxicity Scores for these fractions differed (TS = 59.2, 
4.6, and 10.0, Molecular TS = 78.8, 15.0, and 6.9, respectively). Nevertheless, the 
similarity in both the sequences obtained (Table 1) and the LD50s (Table 2) suggest 
that the toxins present in these fractions are likely to be similar isoforms. No other 
toxins were found to show lethality at the pre-determined cut-off value. Mice injected 
with fractions 3, 4, 5, and 8 showed evident manifestations of respiratory paralysis, 
indicating that the cause of death was neurotoxin-induced respiratory arrest. 
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 The toxicity analysis of fractions strongly suggests that other venom 
components, such as PLA2s, do not play a central role in the overall toxicity. Despite 
the fact that neurotoxic PLA2s occur in many elapid snake venoms [36], and although 
neurotoxic PLA2s have been described in some Naja sp venoms [37], in general the 
neurotoxicity of cobra venoms is based on the action of post-synaptically acting 
3FTxs. Likewise, other minor components present in N. melanoleuca venom do not 
seem to exert lethal effects either, as judged by our toxicity screening. 
According to their Toxicity Scores, the most therapeutically relevant targets of 
N. melanoleuca to be neutralized with antivenom were found to be homologs of 
Alpha-neurotoxin NTX-1 from N. sputratix (Q9YGJ6), Short neurotoxin 1 from N. 
melanoleuca (P01424), Long neurotoxin 2 from N. melanoleuca (P01388), and Long 
neurotoxin OH-55 O. hannah (Q53B58) which are D-neurotoxins that bind to the 
nicotinic acetylcholine receptor, thereby abrogating neuromuscular transmission. 
 
3.3 Immunoprofiling of antivenoms  
Three polyspecific antivenoms, distributed in sub-Saharan Africa, were tested for 
their ability to recognize N. melanoleuca crude venom and fractions by ELISA. First, 
ELISA titration curves were determined against immobilized crude venom with the 
highest binding found to be VINS African, followed by SAVP, and VINS Central 
Africa, when normalized according to protein concentration (Figure 5). The 
immunization mixture of both VINS African and SAVP contain the venom of N. 
melanoleuca, whereas VINS Central Africa solely consists of venom from three 
species of the Viperidae family and Dendroaspis polylepis. Thus, cross-reactivity 
between similar toxins present in these species and N. melanoleuca is likely to exist. 
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When using solid-phase immunoassays of antivenoms against crude venoms, 
prediction of cross-reactivity may be of limited value as antibodies tend to bind to the 
highly immunogenic venom components, which are not always the most medically 
relevant ones. Therefore, it is important to consider the recognition pattern for 
antivenoms against individual venom components or fractions. To further investigate 
these immunorecognition patterns, all three antivenoms were subjected to yet another 
ELISA assay against the different venom fractions (Figure 6). From these results it 
was observed that the three antivenoms generally have a similar recognition pattern. 
However, the SAVP antivenom does appear to have higher antibody titers than the 
other antivenoms against the medically most relevant fractions containing the α-
neurotoxins (fractions 3, 4, 5, and 8) (see Figure 6). 
 
4.0 Concluding remarks and outlook 
In the present study, the venom of N. melanoleuca was, for the first time, subjected to 
a thorough toxicovenomics analysis. This revealed that the venom was dominated by 
three-finger toxins (57.1 w% of the venom) and phospholipase A2s (12.9 w% of the 
venom), of which particularly the three-finger toxins were determined to be the most 
toxic fractions of the venom evaluated by their Toxicity Score. Additionally, other 
protein families (CRISPs, nerve growth factor, Kunitz-type serine protease inhibitor, 
ohanin/vespryn, SVMPs, DNA/RNA non-specific endonuclease, 
endonuclease/phosphodiesterase, flavin monoamine oxidase, glutathione peroxidase, 
Type-B carboxylesterase/lipase, and selectins) were determined to be present in the 
venom. Immunoprofiling of three antivenoms by ELISA with the different fractions 
of N. melanoleuca venom revealed a similar pattern of immunorecognition, although 
the South African antivenom exhibited slightly higher signals against the 
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toxicologically relevant neurotoxins. Our toxicovenomic observations indicate that an 
effective antivenom against the venom of N. melanoleuca should contain neutralizing 
antibodies against venom components having homology to the D-neurotoxins Alpha-
neurotoxin NTX-1 from N. sputratix (Q9YGJ6), Short neurotoxin 1 from N. 
melanoleuca (P01424), Long neurotoxin 2 from N. melanoleuca (P01388), and Long 
neurotoxin OH-55 O. hannah (Q53B58). Hopefully, these studies may help lay the 
foundation for developing more efficacious antivenoms, based on traditional or novel 
biotechnological approaches. 
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Figure legends 
 
Figure 1: Naja melanoleuca in a raised position displaying its characteristic cobra 
hood. 
 
Figure 2: Separation of N. melanoleuca venom proteins using RP-HPLC (A), 
followed by SDS-PAGE (B). Two mg of venom were fractionated on a C18 column 
and eluted with an acetonitrile gradient (dashed line), followed by further separation 
of protein fractions by SDS-PAGE under reducing conditions. Molecular weight 
markers (M) are indicated in kDa. Coomassie-stained bands were excised, in-gel 
digested with trypsin, and subjected to MALDI-TOF/TOF analysis for assignment to 
protein families, as shown in Table 1.   
 
Figure 3: Composition of the N. melanoleuca venom proteome according to protein 
families, expressed as percentages of total protein content based on w%.  3FTx: three-
finger toxins; PLA2: phospholipase A2s; CRISP: cysteine-rich secretory proteins; 
NGF: Nerve growth factors; KUN: Kunitz-type serine protease inhibitors; OHA: 
Ohanins/vespryns; MP: Snake venom metalloproteinases; DRE: DNA/RNA non-
specific endonucelases;  PDE: Endonucleases/Phosphodiesterases; FMO: Flavin 
monoamine oxidases; GPF: glutathione peroxidases; CELF:  Type-B 
carboxylesterases/lipases; SUSHI: Selectins; UNK: Unknown.  
 
Figure 4: (A) Comparison of the phospholipase A2 activity of 20 µg of the venoms of 
N. melanoleuca, N. mossambica, N. nigricollis, and Bothrops asper on 4-nitro-3-
octanoyloxybenzoic acid synthetic substrate. (B) Comparison of the proteolytic 
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activity of 20 µg of venoms of N. melanoleuca, N. mossambica, N. nigricollis, and 
Bothrops asper on azocasein substrate. Each bar represents mean ± SD of triplicates. 
 
Figure 5: ELISA titrations of antivenoms against immobilized crude venoms of N. 
melanoleuca. SAVP: SAIMR Polyvalent Snake Antivenom from South African 
Vaccine Producers. African: Snake Venom Antiserum (African) from VINS 
Bioproducts Ltd. Central Africa: Snake Venom Antiserum (Central Africa) from 
VINS Bioproducts Ltd. Control: Normal horse serum. Each point represents mean r 
SD of triplicate wells. Antivenom titrations are represented as volumetric dilutions in 
(A), or as protein concentrations in (B). 
 
Figure 6: ELISA-based immunoprofiling of antivenoms against HPLC fractions of N. 
melanoleuca venom. For identification of venom fractions see Table 2. SAVP: 
SAIMR Polyvalent Snake Antivenom from South African Vaccine Producers. 
African: Snake Venom Antiserum (African) from VINS Bioproducts Ltd. Central 
Africa: Snake Venom Antiserum (Central Africa) from VINS Bioproducts Ltd. 
Control: Normal horse serum. Each bar represents mean r SD of triplicate wells.  
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SD
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E m
ass estim
ations, in kD
a. Possible, although unconfirm
ed/am
biguous am
ino acid m
odifications suggested by the autom
ated identification 
softw
are are show
n in parentheses, w
ith the follow
ing abbreviations: da: deam
idated;  na: N
a cation;  dh: dehydrated; ca: carbam
ylated. 
** Protein fam
ily abbreviations: 3FTx: Three-finger toxin; PLA
2 : Phospholipase A
2 ; C
R
ISP: C
ysteine-rich secretory protein; N
G
F: N
erve grow
th factor; 
K
U
N
: K
unitz-type serine protease inhibitor; O
H
A
: O
hanin/vespryn; M
P: M
etalloproteinase; D
R
E: D
N
A
/R
N
A
 non sp-endonuclease; CTL: C
-type lectin; 
PD
E: Endonuclease/Phosphodiesterase; FM
O
: Flavin m
onoam
ine oxidase; G
PF: G
lutathione peroxidase; C
ELF: Type-B
 carboxylesterase/lipase; SU
SH
I: 
Selectins – cell adhesion (http://pfam
.xfam
.org/fam
ily/PF00084); U
N
K
: U
nknow
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 Table 2: Lethality and Toxicity Score of RP-HPLC fractions of the venom of N. melanoleuca 
Peak 
w%
 
mol%
 
Protein family 
LD
50 
(95%
 conf. 
limits) 
Reported LD
50  
(mg/kg) 
Toxicity score 
w%
 / LD
50 
(kg/mg) 1 
M
olecular 
Toxicity score 
mol%
 / LD
50 
(kg/mg) 1 
W
hole venom
 
100 
100 
 
0.66 
(0.49-0.92) 
0.289*
 
151 
151 
3 
7.7 
10.2 
3FTx 
A
lpha-neurotoxin N
TX
-1 Naja sputatrix; Q
9Y
G
J6 
Short neurotoxin 1 Naja melanoleuca; P01424 
0.13  
(0.06-0.34) 
 
 
59.2 
78.8 
4 
0.6 
0.9 
3FTx 
A
lpha-neurotoxin N
TX
-1 Naja sputatrix; Q
9Y
G
J6 
Short neurotoxin 1 Naja melanoleuca; P01424 
0.13 
(0.05-0.33) 
 
4.6 
6.9 
5 
1.1 
1.6 
3FTx 
A
lpha-neurotoxin N
TX
-1 Naja sputatrix; Q
9Y
G
J6 
Short neurotoxin 1 Naja melanoleuca; P01424 
0.11  
(0.03-0.23) 
 
 
10 
15.0 
7 
1.4 
1.9 
3FTx 
Short-chain 3FTx 7 Bungarus flaviceps;D
5J9P4 
Long neurotoxin 2 Naja melanoleuca;P01388 
>0.53 
 
<2.6 
<3.6 
8 
13.2 
17.3 
3FTx 
W
eak toxin S4C11 Naja melanoleuca; P01400 
Long neurotoxin O
H
-55 O.hannah; Q
53B
58 
Long neurotoxin 2 Naja melanoleuca; P01388 
0.15 
(0.06-0.42) 
>20 (P01400) 
[9] 
88 
115.5 
9 
2.0 
2.7 
3FTx 
3FTx-D
en-15 Denisonia devisi; R4FID
4 
M
uscarinic toxin-like prot.2 N. kaouthia; P82463 
Long neurotoxin O
H
-55 O.hannah; Q
53B
58 
M
uscarinic toxin-like prot B.multicinctus; Q
9W
727 
>0.53 
 
<3.8 
<5.0 
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 10 
0.9 
1.2 
3FTx 
3FTx-D
en-15 Denisonia devisi; R4FID
4 
3FTx-Ech-35 Echiopsis curta; R
4G
7H
1 
Long neurotoxin O
H
-55 O.hannah; Q
53B
58 
B
ucandin Bungarus candidus; P81782 
C
ytotoxin 1 Naja melanoleuca; P01448 
>0.53 
1.36 (P01448) 
[11] 
<1.7 
<2.2 
11 
0.6 
0.9 
3FTx 
C
ytotoxin 1 Naja melanoleuca; P01448 
>0.53 
1.36 (P01448) 
[11] 
<1.1 
<1.7 
12 
3.8 
6.0 
K
unitz-type SP inhibitor 2 Naja nivea; P00986 
>0.53 
 
<7.2 
<11.4 
13 
4.8 
(1:1 m
ix) 
5.2 
(1:1 m
ix) 
PLA
2  
PLA
2  1 Naja melanoleuca; P00599 
PLA
2  D
E-III Naja melanoleuca; P00601 
PLA
2  4 Naja sagittifera; Q
6T179 
3FTx 
C
ytotoxin 1 Naja melanoleuca; P01448 
>0.53 
1.36 (P01448) 
[11] 
<9.1 
<9.9 
14 
10.8 
(1:3 m
ix) 
8.3 
(1:3 m
ix) 
PLA
2  
PLA
2  D
E-II Naja melanoleuca; P00600 
PLA
2  D
E-III Naja melanoleuca; P00601 
3FTx 
C
ytotoxin 1 Naja melanoleuca; P01448 
>0.53 
1.36 (P01448) 
[11] 
<20.4 
<15.6 
15 
12.7 
(1:1 m
ix) 
14.0 
(1:1 m
ix) 
PLA
2  
PLA
2  D
E-III Naja melanoleuca; P00601 
PLA
2  m
uscarinic inhibitor Naja sputatrix; Q
92084 
3FTx 
C
ytotoxin 1 Naja melanoleuca; P01448 
>0.53 
1.36 (P01448) 
[11] 
<24.0 
<26.5 
16 
1.7 
(1:3 m
ix) 
2.3 
(1:3 m
ix) 
PLA
2  
PLA
2  D
E-III Naja melanoleuca; P00601 
PLA
2  m
uscarinic inhibitor Naja sputatrix; Q
92084 
3FTx 
C
ytotoxin 1 Naja melanoleuca; P01448 
>0.53 
 
<3.2 
<4.4 
3 
 17 
3.4 
5.1 
3FTx 
C
ytotoxin hom
olog 2 Naja melanoleuca; P01474 
>0.53 
 
<6.4 
<9.6 
18 
4.2 
6.3 
3FTx 
C
ytotoxin hom
olog 2 Naja melanoleuca; P01474 
>0.53 
 
<7.9 
<11.8 
19 
0.7 
(1:1 m
ix) 
0.8 
(1:1 m
ix) 
NGF 
N
erve grow
th factor Naja naja; P01140 
N
erve grow
th factor Naja naja; P01140 
3FTx 
W
eak toxin C
M
-1c H.haemachatus; P25676 
>0.53 
 
54 (P25676) 
[38] 
<1.3 
<1.5 
20 
1.5 
(1:2 m
ix) 
1.9 
(1:2 m
ix) 
OHA 
Thaicobrin Naja kaouthia; P82885 
 3FTx 
W
eak toxin C
M
-1c H.haemachatus; P25676 
>0.53 
 
54 (P25676) 
[38] 
<2.8 
<3.6 
21 
4.8 
6.7 
SUSHI 
C
' decay-accelerating factor O.hannah; ETE59511 
C
'-decay-accelerating factor O.hannah; V
8N
C
63 
W
eak toxin C
M
-2 Naja haje; P01415 
>0.53 
 
<9.1  
<12.7 
22 
0.6 
0.4 
CTL 
C
TL LP-Pse-6 Pseudonaja modesta; R4G
314 
>0.53 
 
<1.1 
<0.7 
 
 
 
 
 
 
 
 
1Toxicity Score is defined as the ratio of protein fraction abundance (%
) in the venom
 to its estim
ated m
edian lethal dose (LD
50 ), w
hereas 
M
olecular Toxicity Score corresponds to the ratio of protein abundance in m
olar term
s  (%
) to LD
50 . In the case of crude venom
, the %
 
abundance w
as 100%
. 
 * : http://snakedatabase.org/pages/LD
50.php#legendA
ndD
efinitions  
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